Atacicept in Multiple Glomerular Diseases

Inclusion Criteria21

• Weight of at least 40 kg
• On a stable prescribed standard of care (SoC) treatment regimen according to local guidelines and the specific requirements for each disease
• Systolic blood pressure ≤160 mmHg and diastolic blood pressure ≤90 mmHg at Screening. For participants aged ≥10 to \<18 years, the average of 3 separate systolic and/or diastolic blood pressures \<95th percentile for age, gender, and height
• Diagnosis of IgAN, IgAVN, pMN, MCD, FSGS, or primary nephrotic syndrome
• For patients enrolling in IgAN cohorts (eligibility varies by cohort):
• Age ≥ 10 years
• Biopsy proven IgAN or IgAVN,
• UPCR ≥ 0.5 g/g
• eGFR≥ 20 mL/min/1.73m2
• For patients enrolling in pMN cohorts (eligibility varies by cohort):
• Age ≥ 18 years
• Biopsy-proven pMN
• Anti PLA2R antibodies ≥ 25 RU/mL
• UPCR ≥ 1.5 g/g
• At low risk for spontaneous remission (based on severity or duration of disease)
• For patients enrolling in Nephrotic Syndrome cohorts (MCD, FSGS, or pediatric idiopathic nephrotic syndrome):
• Age ≥ 10 years
• eGFR≥30 mL/min/1.73m2
• Biopsy diagnosis of primary MCD or FSGS (adults) or challenging clinical course with steroids in children (frequenlty relapsing, steroid-dependent, or steroid-resistant)
• UPCR ≥ 1.0 g/g at Screening,
• Evidence of anti-nephrin antibodies